OncoCyte Statistics
Total Valuation
OncoCyte has a market cap or net worth of $42.90 million. The enterprise value is $38.96 million.
| Market Cap | 42.90M |
| Enterprise Value | 38.96M |
Important Dates
The next estimated earnings date is Thursday, August 8, 2024, before market open.
| Earnings Date | Aug 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
OncoCyte has 13.36 million shares outstanding. The number of shares has increased by 38.59% in one year.
| Shares Outstanding | 13.36M |
| Shares Change (YoY) | +38.59% |
| Shares Change (QoQ) | -0.02% |
| Owned by Insiders (%) | 12.80% |
| Owned by Institutions (%) | 52.57% |
| Float | 6.01M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 31.04 |
| Forward PS | 23.78 |
| PB Ratio | 3.70 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 28.19 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.79, with a Debt / Equity ratio of 0.29.
| Current Ratio | 0.79 |
| Quick Ratio | 0.89 |
| Debt / Equity | 0.29 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -703.37 |
Financial Efficiency
Return on equity (ROE) is -144.40% and return on invested capital (ROIC) is -269.74%.
| Return on Equity (ROE) | -144.40% |
| Return on Assets (ROA) | -51.90% |
| Return on Capital (ROIC) | -269.74% |
| Revenue Per Employee | $30,043 |
| Profits Per Employee | -$888,283 |
| Employee Count | 46 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.87% in the last 52 weeks. The beta is 0.98, so OncoCyte's price volatility has been similar to the market average.
| Beta (5Y) | 0.98 |
| 52-Week Price Change | -25.87% |
| 50-Day Moving Average | 2.88 |
| 200-Day Moving Average | 2.98 |
| Relative Strength Index (RSI) | 60.08 |
| Average Volume (20 Days) | 74,422 |
Short Selling Information
The latest short interest is 458,324, so 3.43% of the outstanding shares have been sold short.
| Short Interest | 458,324 |
| Short Previous Month | 374,595 |
| Short % of Shares Out | 3.43% |
| Short % of Float | 7.63% |
| Short Ratio (days to cover) | 14.00 |
Income Statement
In the last 12 months, OncoCyte had revenue of $1.38 million and -$40.86 million in losses. Loss per share was -$5.08.
| Revenue | 1.38M |
| Gross Profit | 305,000 |
| Operating Income | -40.25M |
| Pretax Income | -40.15M |
| Net Income | -40.86M |
| EBITDA | -38.55M |
| EBIT | -40.09M |
| Loss Per Share | -$5.08 |
Balance Sheet
The company has $7.28 million in cash and $3.34 million in debt, giving a net cash position of $3.94 million or $0.30 per share.
| Cash & Cash Equivalents | 7.28M |
| Total Debt | 3.34M |
| Net Cash | 3.94M |
| Net Cash Per Share | $0.30 |
| Equity (Book Value) | 11.59M |
| Book Value Per Share | 0.87 |
| Working Capital | -1.79M |
Cash Flow
In the last 12 months, operating cash flow was -$17.48 million and capital expenditures $49,000, giving a free cash flow of -$17.43 million.
| Operating Cash Flow | -17.48M |
| Capital Expenditures | 49,000 |
| Free Cash Flow | -17.43M |
| FCF Per Share | -$2.11 |
Margins
Gross margin is 22.07%, with operating and profit margins of -2,912.66% and -2,956.66%.
| Gross Margin | 22.07% |
| Operating Margin | -2,912.66% |
| Pretax Margin | -2,905.14% |
| Profit Margin | -2,956.66% |
| EBITDA Margin | -2,789.36% |
| EBIT Margin | -2,901.01% |
| FCF Margin | -1,261.51% |
Dividends & Yields
OncoCyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -38.59% |
| Shareholder Yield | -38.59% |
| Earnings Yield | -95.25% |
| FCF Yield | -40.64% |
Analyst Forecast
The average price target for OncoCyte is $4.06, which is 26.48% higher than the current price. The consensus rating is "Buy".
| Price Target | $4.06 |
| Price Target Difference | 26.48% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on July 25, 2023. It was a reverse split with a ratio of 1:20.
| Last Split Date | Jul 25, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
OncoCyte has an Altman Z-Score of -7.3 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -7.3 |
| Piotroski F-Score | 4 |